The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...

The past few months have been rather gloomy in the health research space in Kenya. It all started with withdrawal of the USAID funding, bringing to a halt some ongoing research programmes in the ...

Research shows RSV leads to high hospitalization rates in adults, emphasizing the importance of enhanced surveillance and ...

For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

A rare cell in the lining of lungs is fundamental to the organ-wide response necessary to repair damage from toxins like ...

GSK has become the first pharma company to get regulatory approval for a vaccine against respiratory syncytial virus (RSV), setting up what looks set to be a highly lucrative – and likely ...